This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

StemCells, Inc. CEO Discusses Interim 6-Month Data From Spinal Cord Injury Trial - Call Transcript

StemCells, Inc. (STEM)

Interim 6-Month Data from Spinal Cord Injury Trial Call

September 4, 2012 11:30 am ET

Executives

Martin M. McGlynn – President, Chief Executive Officer & Director

Armin Curt, M.D. – Professor & Chairman of the Spinal Cord Injury Center University of Zurich

Stephen Huhn, M.D., FACS, FAAP – Vice President & Head of CNS Program

Analyst

Stephen M. Dunn – LifeTech Capital

[Jason Colbert – Max M Group]



Presentation



Operator



Welcome to the StemCells, Inc. webcast on interim six month data from spinal cord injury trial. At this time all participants are in a listen only mode. We will be facilitating a question and answer session towards the end of today’s conference. (Operator Instructions) As a reminder, the conference is being recorded for replay purposes. I would now like to turn the presentation over to the host for today’s conference Mr. Martin McGlynn, Chief Executive Officer.

Martin M. McGlynn

Welcome to StemCells, Inc.’s webcast during which we will present a summary of the Phase I/II data in our chronic spinal cord injury trial which is being conducted in Balgrist Switzerland. Before we go any further I would like to introduce you to Dr. Armin Curt who is on the line on the call who is professor and chairman of the Spinal Cord Injury Center at the University of Zurich and is the medial director of the Paraplegic Center at Balgrist University Hospital and Dr. Curt is the principle investigator on this study.

Dr. Curt will make the majority of the remarks and conduct most of the presentation. He will be preceded by Dr. Stephen Huhn who is a neurosurgeon and heads our CNS Program and is the vice president of StemCells, Inc. Stephen will start off with a few introductory slides and then when Dr. Curt is finished with his presentation Stephen will wrap up on the presentation and then thereafter we will open it up to Q&A. Without any further adieu I’d like to hand you over to Dr. Stephen Huhn.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 17,841.98 -86.22 -0.48%
S&P 500 2,080.15 -9.31 -0.45%
NASDAQ 4,919.6440 -19.6830 -0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs